- AstraZeneca dives into regulatory T cell therapies in deal with Quell Therapeutics Endpoints News
- AstraZeneca pays $85M to Quell Type 1 diabetes with ‘one and done’ cell therapy FierceBiotech
- AstraZeneca signs $2 billion agreement with Quell to develop cell therapies Reuters
- Quell Therapeutics Signs a Collaboration, Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies for Autoimmune Diseases GlobeNewswire
- Astra Enters Into $2 Billion-Plus Pact With UK Biotech Quell Bloomberg
- View Full Coverage on Google News
Read original article here